Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Total Current Assets

All assets expected to be converted to cash or used up within one year.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Total Current Assets · Q1 FY2026 · quarter ended Mar 2026

Total current assets falls 22.2% from a year ago

Total current assets stood at $216.88M at the end of Q1 FY2026, down 22.2% from a year earlier and down 10.2% from the prior quarter. Over 3 fiscal years it compounded at -15.7% a year.

Context

  • Total current assets amounted to 88.4% of total assets at the end of Q1 FY2026, up 4.3 pp from a year earlier.
  • Total current assets increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total current assets keeps falling in the next quarterly balance sheet after a -22.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$216.88M-10.2% QoQ
Last fiscal yearDec 2025
$241.45M-21.1% YoY
Year agoMar 2025
$278.79M-22.2% since
Total Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.2%——
1 year-21.1%——
3-year CAGR-15.7%——
5-year CAGR——
10-year CAGR——

Total Current Assets history

USD · from the balance sheet

Latest · FY2025
241.45M USD
Year-over-year change
-21.1%
4-year CAGR
-10.7%

Total Current Assets vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -22.2% is the 4th highest of 11, against a peer median of -39.4%.
  • Total current assets amounts to 88.4% of total assets for ARCT, versus a peer median of 84.7%.
ARCT Competitors
Total Current Assets for ARCT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVAXNovavax, Inc.Mar 2026$850.82M USD-2.0%-16.9%81.6%
VIRVir Biotechnology, Inc.Mar 2026$522.99M USD-43.9%-41.1%51.0%
ABUSArbutus Biopharma CorporationMar 2026$277.01M USD+137.2%-14.5%99.9%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$263.2M USD-39.3%-22.2%98.5%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$216.88M USD-22.2%-15.7%88.4%
VALNValneva SEMar 2026€201.65M EUR-29.8%-19.4%54.1%
BNTCBenitec Biopharma Inc.Mar 2026$186.02M USD+78.8%+173.4%99.5%
RCKTRocket Pharmaceuticals, Inc.Mar 2026$149.83M USD-53.8%-19.1%52.5%
SLNSilence Therapeutics plcMar 2026$102.85M USD-39.4%+7.1%89.3%
PRQRProQR Therapeutics N.V.Mar 2026€87.07M EUR-41.6%-13.5%87.8%
INOInovio Pharmaceuticals, Inc.Mar 2026$39.44M USD-45.1%-42.1%79.2%
Peer median (excluding ARCT) —-39.4%-18.0%84.7%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents370.49M391.88M292.01M237.03M230.91M
Short-term Investments00000
Net Receivables3.37M2.76M32.06M3.97M5.56M
Inventory00000
Other Current Assets08.69M55M64.98M4.97M
Total Current Assets378.96M403.33M386.59M305.98M241.45M
Property, Plant & Equipment (Net)11.26M44.96M40.93M36.21M27.82M
Goodwill00000
Intangible Assets00000
Long-term Investments515K01.89M01.89M
Tax Assets00000
Other Non-current Assets2.08M2.09M01.89M0
Total Non-current Assets13.85M47.05M42.81M38.09M29.7M
Total Assets392.81M450.39M429.4M344.07M271.15M
Account Payables10.06M7.45M5.28M7.19M4.24M
Short-term Debt22.47M60.66M000
Tax Payables01.3M641K00
Deferred Revenue43.48M36.12M47.34M21.94M8.25M
Other Current Liabilities3.58M4.04M18.5M13.31M6.95M
Total Current Liabilities99.54M126.98M81.99M65.49M36.38M
Long-term Debt40.63M0000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)020.07M42.5M12.6M0
Other Non-current Liabilities19.93M2.8M497K00
Total Non-current Liabilities65.07M53.09M68.9M37.6M20.78M
Total Liabilities164.6M180.08M150.89M103.09M57.16M
Common Stock26K27K27K27K28K
Retained Earnings(347.49M)(338.14M)(367.87M)(448.81M)(514.59M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity228.21M270.31M278.51M240.98M213.99M
Total Debt69.15M94.76M30.22M28.55M25M
Net Debt(301.35M)(297.13M)(261.79M)(208.48M)(205.91M)

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.